SLS And IBRX Share 3 Institutional Backers With Big Pharma Giants — As Stanley Druckenmiller Makes Bold Prediction: ‘We’re Gonna Beat Cancer’
New York’s pension fund held $1.42 billion in the three pharma giants versus just under $2 million in SLS and IBRX.